Biohaven Ltd. (BHVN) is up 7.74 percent during Tuesday's trading, gaining $3.35 to trade at $41.60. The stock's rise follows the FDA's acceptance of Biohaven's New Drug Application or NDA for troriluzole, a treatment for spinocerebellar ataxia, and its designation for Priority Review.
BHVN is currently trading at $41.28, up from the previous close of $38.25 on the New York Stock Exchange. The stock has fluctuated between $38.89 and $42.68 during today's session. Trading volume stands at 1.03 million shares, surpassing the average volume of 961,191.
The stock remains within its 52-week range of $26.80 to $62.21, as investors react positively to the potential milestone for Biohaven.
If approved, troriluzole would be the first FDA-approved treatment for this rare neurodegenerative disease, with commercialization expected in 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.